Del Bene Gabriella, Sternberg Cora N
Department of Medical Oncology, San Camillo Forlanini Hospital, Padiglione Flajani, Rome - Italy.
Department of Experimental Medicine, "La Sapienza" University, Rome - Italy.
Urologia. 2017 Aug 1;84(3):130-141. doi: 10.5301/uj.5000230. Epub 2017 Jun 14.
Bladder cancer is the most frequent among the urothelial tumors, and it is responsible for about 2% of all cancer mortality worldwide. The mainstay of chemotherapy treatment, both for muscle-invasive and metastatic disease, is cisplatin-based regimens. In recent years, ground-breaking results have been achieved with immunotherapy, which have led to important breakthroughs in the bladder cancer treatment scenario, with the approval of several new agents. New insights derive from a greater characterization of the tumor genome, which could lead to developing new therapies, more personalized, in the near future.
膀胱癌是尿路上皮肿瘤中最常见的，它在全球所有癌症死亡中占约2%。对于肌肉浸润性和转移性疾病，化疗的主要方案是以顺铂为基础的治疗方案。近年来，免疫疗法取得了突破性成果，随着几种新药物的获批，这些成果在膀胱癌治疗领域带来了重要突破。对肿瘤基因组更深入的特征分析带来了新的见解，这可能会在不久的将来催生出更具个性化的新疗法。
